Alloy Therapeutics

Alloy Therapeutics

  • Founded: 2018
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Drug discovery
  • Drug types: IMM
  • Lead product: Alloy-Gx mouse platform
  • Product link:
  • Funding: $42M D Oct 2022; $75M C Apr 2021
  • Investors: 8VC,¬†Mubadala Capital, Thiel Capital, Presight Capital, Founders Fund

job board

Short description:

Antibody Discovery Platform

Drug notes:

Also offer services for antibody discovery and development

Long description:

Alloy Therapeutics describes itself as a biotechnology ecosystem company that enables pre-competitive drug discovery at all levels. Alloy currently offers licensing in antibody and TCR platforms, drug discovery and optimization services, and subscription-based access to pre-competitive technology. Alloy utilizes highly immunocompetent transgenic mice to produce maximum diversity and epitopic coverage with their ATX-Gx antibody platform. They also offer their ATX-CLC platform for common-light chain bispecific and multispecific discovery as well as their ATX-SiD platform for the discovery of single-domain antibodies. The Keyway TCR Discovery Services offer access to custom therapeutic TCR mimics and engineered TCRs against custom targets.


Alloy Therapeutics
Senior Scientist, Biology
Waltham, MA|7 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy